Wenhu Duan

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4829940/publications.pdf

Version: 2024-02-01

		567281	580821
30	648	15	25
papers	citations	h-index	g-index

31	31	31	1008
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Synthesis of triazolotriazine derivatives as c-Met inhibitors. Molecular Diversity, 2021, 25, 839-846.	3.9	3
2	Design, Synthesis, and Biological Evaluation of IRAK4-Targeting PROTACs. ACS Medicinal Chemistry Letters, 2021, 12, 82-87.	2.8	22
3	Discovery of a Pyrimidinedione Derivative as a Potent and Orally Bioavailable Axl Inhibitor. Journal of Medicinal Chemistry, 2021, 64, 3956-3975.	6.4	9
4	Structure-Guided Development of Small-Molecule PRC2 Inhibitors Targeting EZH2â€“EED Interaction. Journal of Medicinal Chemistry, 2021, 64, 8194-8207.	6.4	25
5	Discovery of pyrrolo[2,3-d]pyrimidine derivatives as potent Axl inhibitors: Design, synthesis and biological evaluation. European Journal of Medicinal Chemistry, 2021, 220, 113497.	5.5	12
6	Discovery and structureÂâ^'Âactivity relationship exploration of pyrazolo[1,5-a]pyrimidine derivatives as potent FLT3-ITD inhibitors. Bioorganic and Medicinal Chemistry, 2021, 48, 116422.	3.0	1
7	DW14006 as a direct AMPKÎ±1 activator improves pathology of AD model mice by regulating microglial phagocytosis and neuroinflammation. Brain, Behavior, and Immunity, 2020, 90, 55-69.	4.1	13
8	DW14006 as a Direct AMPKÎ± Activator Ameliorates Diabetic Peripheral Neuropathy in Mice. Diabetes, 2020, 69, 1974-1988.	0.6	15
9	Design and synthesis of Imidazo[1,2-b]pyridazine IRAK4 inhibitors for the treatment of mutant MYD88 L265P diffuse large B-cell lymphoma. European Journal of Medicinal Chemistry, 2020, 190, 112092.	5.5	16
10	Rational Design, synthesis and biological evaluation of novel triazole derivatives as potent and selective PRMT5 inhibitors with antitumor activity. Journal of Computer-Aided Molecular Design, 2019, 33, 775-785.	2.9	14
11	Targeting PRMT5 Activity Inhibits the Malignancy of Hepatocellular Carcinoma by Promoting the Transcription of HNF4Î±. Theranostics, 2019, 9, 2606-2617.	10.0	40
12	Discovery of 2-substituted-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-1,2,3,4-tetrahydroisoquinoline-6-carboxamide as potent and selective protein arginine methyltransferases 5 inhibitors: Design, synthesis and biological evaluation. European Journal of Medicinal Chemistry, 2019, 164, 317-333.	5.5	19
13	Discovery of Potent Irreversible Pan-Fibroblast Growth Factor Receptor (FGFR) Inhibitors. Journal of Medicinal Chemistry, 2018, 61, 9085-9104.	6.4	25
14	Evaluation of Deuterium-Labeled JNJ38877605: Pharmacokinetic, Metabolic, and in Vivo Antitumor Profiles. Chemical Research in Toxicology, 2018, 31, 1213-1218.	3.3	32
15	Synthesis and Bioevaluation of Shikonin Derivatives. Letters in Drug Design and Discovery, 2018, 15, 945-950.	0.7	4
16	Discovery of cycloalkyl-fused N-thiazol-2-yl-benzamides as tissue non-specific glucokinase activators: Design, synthesis, and biological evaluation. European Journal of Medicinal Chemistry, 2017, 139, 128-152.	5.5	12
17	Potent, Selective, and Cell Active Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor Developed by Structure-Based Virtual Screening and Hit Optimization. Journal of Medicinal Chemistry, 2017, 60, 6289-6304.	6.4	53
18	Discovery of 1,3â€Diarylâ€pyridones as Potent <scp>VEGFR</scp>â€2 Inhibitors: Design, Synthesis, and Biological Evaluation. Chemical Biology and Drug Design, 2016, 87, 694-703.	3.2	5

#	Article	IF	Citations
19	Discovery of 6-(difluoro(6-(4-fluorophenyl)-[1,2,4]triazolo[4,3- b][1,2,4]triazin-3-yl)methyl)quinoline as a highly potent and selective c-Met inhibitor. European Journal of Medicinal Chemistry, 2016, 116, 239-251.	5.5	27
20	Design, synthesis and biological evaluation of pyrazolylaminoquinazoline derivatives as highly potent pan-fibroblast growth factor receptor inhibitors. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 2594-2599.	2.2	7
21	Discovery of Substituted 1H-Pyrazolo[3,4-b]pyridine Derivatives as Potent and Selective FGFR Kinase Inhibitors. ACS Medicinal Chemistry Letters, 2016, 7, 629-634.	2.8	58
22	Discovery of 3-(5â€²-Substituted)-Benzimidazole-5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1H-indazoles as Potent Fibroblast Growth Factor Receptor Inhibitors: Design, Synthesis, and Biological Evaluation. Journal of Medicinal Chemistry, 2016, 59, 6690-6708.	6.4	44
23	Simm530, a novel and highly selective c-Met inhibitor, blocks c-Met-stimulated signaling and neoplastic activities. Oncotarget, 2016, 7, 38091-38104.	1.8	6
24	Discovery of anilinopyrimidine-based naphthamide derivatives as potent VEGFR-2 inhibitors. MedChemComm, 2015, 6, 1375-1380.	3.4	7
25	Discovery of Anilinopyrimidines as Dual Inhibitors of c-Met and VEGFR-2: Synthesis, SAR, and Cellular Activity. ACS Medicinal Chemistry Letters, 2014, 5, 673-678.	2.8	30
26	Discovery of a New Series of Naphthamides as Potent VEGFR-2 Kinase Inhibitors. ACS Medicinal Chemistry Letters, 2014, 5, 592-597.	2.8	13
27	One-Pot Synthesis of Isoindolinones via Three-Component Mannich/Lactamization Cascade Reaction. Synthetic Communications, 2012, 42, 1115-1127.	2.1	13
28	Oâ€Linked Triazolotriazines: Potent and Selective câ€Met Inhibitors. ChemMedChem, 2012, 7, 1276-1285.	3.2	18
29	A Novel Bifunctional Sulfonamide Primary Amineâ€Catalyzed Enantioselective Conjugate Addition of Ketones to Nitroolefins. Advanced Synthesis and Catalysis, 2008, 350, 2194-2198.	4.3	68
30	Efficient, Enantioselective Organocatalytic Synthesis of Trichostatin A. Advanced Synthesis and Catalysis, 2006, 348, 1228-1234.	4.3	36